Skip to main content
. Author manuscript; available in PMC: 2024 Jul 5.
Published in final edited form as: Lancet Oncol. 2023 Aug;24(8):925–935. doi: 10.1016/S1470-2045(23)00275-9

Figure 1: Maximal percentage reduction of target lesion from baseline by tumour histology and FGFRalt by IRC assessment.

Figure 1:

The best overall response was recorded from the start of study treatment to end of study, prior to progressive disease and subsequent anticancer therapy (subsequent surgery/procedure, subsequent radiotherapy, and subsequent systemic therapy), taking into account any requirement for confirmation. Disease evaluations were based on RECIST v1·1, maximum percentage reduction from baseline was calculated in sum of target lesion diameters; for disease evaluations based on RANO, maximum percentage reduction from baseline was calculated in sum of product of perpendicular dimension. Maximum percentage increase of target lesion from baseline greater than 100% was set to 100%.

alt=alterations. DNET=dysembryoplastic neuroepithelial tumour. IRC=independent review committee. MRI=magnetic resonance imaging. NSCLC=non-small cell lung cancer. RANO=Response Assessment in Neuro-Oncology. RECIST=Response Evaluation Criteria in Solid Tumors.